+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06799338

Use of Lenacapavir with Optimized Background Treatment for Adults with HIV-1 in France A Retrospective Observational Study

Led by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Updated on 2025-05-22

80

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to describe the real-world use of Lenacapavir LEN combined with an optimized background regimen OBR in people with multidrug-resistant HIV-1 infection in France. Multidrug-resistant HIV-1 can lead to treatment failures, increased risk of hospitalization, progression to AIDS, and death. LEN is a first-in-class capsid inhibitor that has shown promising results in clinical trials, including the CAPELLA phase 3 trial, which demonstrated high rates of viral suppression and increased CD4 T cell counts. LEN can be administered subcutaneously every six months or orally weekly due to its long-acting properties. In France, LEN became publicly available on June 20, 2023, and its use is validated by multidisciplinary hospital committees. This study is a retrospective observational national multicenter study that collects data from medical records of patients who started LEN between June 20, 2023, and June 30, 2024. No additional visits or samples are required, and all treatment decisions are made as part of routine care. Participants medical records will be reviewed to describe their baseline clinical and biological profiles and to monitor whether LEN injections continue at 26 and 52 weeks after starting treatment. Data collection will be retrospective, with some participants having prospective follow-up if their 52-week period is not complete. The study will measure how many participants receive LEN injections at weeks 26 and 52, helping to understand its use in everyday clinical settings in France.

CONDITIONS

Brief Title

Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France

Research Team

Y

Yasmine DUDOIT

R

Romain PALICH, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here